Evidence map›Paper›PMID 30782713›Full record

ArticleBMJ open2019

Development of a binational thyroid cancer clinical quality registry: a protocol paper.

Liane J Ioannou, Jonathan Serpell, Joanne Dean, Cino Bendinelli, Jenny Gough, Dean Lisewski, Julie A Miller, Win Meyer-Rochow, Stan Sidhu, Duncan Topliss and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Liane J IoannouDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Jonathan SerpellEndocrine Surgery Unit, Alfred Hospital, Melbourne, Victoria, Australia.
Joanne DeanDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Cino BendinelliDepartment of Surgery, John Hunter Hospital, New Lambton Heights, New South Wales, Australia.
Jenny GoughBreast and Endocrine Surgery, The Wesley Hospital, Queensland, Australia.
Dean LisewskiDepartment of General Surgery, Fiona Stanley Hospital, Perth, Western Australia, Australia.
Julie A MillerEndocrine Surgery Unit, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Win Meyer-RochowDepartment of Surgery, Waikato Hospital, Hamilton, New Zealand.
Stan SidhuEndocrine Surgery Unit, University of Sydney, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Duncan ToplissDepartment of Endocrinology and Diabetes, Alfred Health, Melbourne, Victoria, Australia.
David WaltersBreast and Endocrine Surgical Unit, University of Adelaide, The Queen Elizabeth Hospital, Sydney, New South Wales, Australia.
John ZalcbergDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Susannah AhernDepartment of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe occurrence of thyroid cancer is increasing throughout the developed world and since the 1990s has become the fastest increasing malignancy. In 2014, a total of 2693 Australians and 302 New Zealanders were diagnosed with thyroid cancer, with this number projected to rise to 3650 in 2018. The purpose of this protocol is to establish a binational population-based clinical quality registry with the aim of monitoring and improving the quality of care provided to patients diagnosed with thyroid cancer in Australia and New Zealand. METHODS AND ANALYSIS: The Australian and New Zealand Thyroid Cancer Registry (ANZTCR) aims to capture clinical data for all patients over the age of 16 years with thyroid cancer, confirmed by histopathology report, who have been diagnosed, assessed or treated at a contributing hospital. A multidisciplinary steering committee was formed which, with operational support from Monash University, established the ANZTCR in early 2017. The pilot phase of the registry is currently operating in Victoria, New South Wales, Queensland, Western Australia and South Australia, with over 20 sites expected to come on board across Australia in 2018. A modified Delphi process was undertaken to determine the clinical quality indicators to be reported by the registry, and a minimum data set was developed comprising information regarding thyroid cancer diagnosis, pathology, surgery and 90-day follow-up. FUTURE PLANS: The establishment of the ANZTCR provides the opportunity for Australia and New Zealand to further understand current practice in the treatment of thyroid cancer and identify variation in outcomes. The engagement of endocrine surgeons in supporting this initiative is crucial. While the pilot registry has a focus on early clinical outcomes, it is anticipated that future collection of longer term outcome data particularly for patients with poor prognostic disease will add significant further value to the registry.

Indexed as

International CooperationAustraliaDelphi TechniqueHumansNew ZealandOutcome Assessment, Health CareQuality Indicators, Health CareRegistriesThyroid Neoplasmsendocrine tumoursquality in health care

Identifiers

PMID30782713
PMCPMC6352782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.